Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer
September 17, 2021 08:30 ET
|
Corcept Therapeutics Incorporated
Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial featured in a proffered paper oral presentation at ESMO 2021Results show statistically significant and clinically relevant...
Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021
September 09, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at the upcoming ESMO conference on September 17, 2021Results show benefit...
William Guyer to join Corcept as Chief Development Officer
August 12, 2021 17:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 29, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 22, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...
Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer
July 12, 2021 08:30 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
June 22, 2021 08:30 ET
|
Corcept Therapeutics Incorporated
Enrollment stopped in RELIANT trialAntitumor activity observed in heavily pretreated patients with metastatic pancreatic cancer, including those previously treated with nab-paclitaxel; addition of...
Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical
June 15, 2021 08:30 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors
June 10, 2021 07:30 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results
May 06, 2021 16:10 ET
|
Corcept Therapeutics Incorporated
In a 178-patient, controlled, Phase 2 trial, women with platinum-resistant ovarian cancer who received relacorilant plus nab-paclitaxel experienced improved progression free survival (PFS) compared to...